Articles from BostonGene

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, and Georgetown University’s Lombardi Comprehensive Cancer Center today announced a collaboration to explore the effectiveness of immune system profiling to monitor patients with gastrointestinal (GI) cancers receiving combinations of immunotherapy and anti-VEGF inhibitors in the microscopic residual disease (MRD) setting.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced that three abstracts have been accepted for poster presentations at the 2024 San Antonio Breast Cancer Symposium (SABCS), to take place December 10 - 13, 2024, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. BostonGene will also exhibit at booth 1317.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the selection of 10 abstracts for poster presentations and two abstracts for online publication at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held December 7-10, 2024, in San Diego, California. BostonGene will exhibit in booth #1955.

BostonGene, a leading provider of AI-driven, molecular and immune profiling solutions today announced that four abstracts have been accepted for presentation at the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, taking place November 19 - 23 at the Vancouver Convention Centre in Vancouver, British Columbia, Canada.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced today it has reached a remarkable milestone by winning five categories at the 2024 Pharmaceutical Technology Excellence Awards. The company was honored in Business Expansion, Research and Development (R&D), Innovation, Product Launches and Marketing, marking a significant achievement in its ongoing mission to advance cancer care through transformative technologies.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the Company will present six posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting taking place November 6-10, 2024 at the George R. Brown Convention Center in Houston, Texas. The research, conducted in collaboration with leading cancer centers, showcases the impact of BostonGene’s technology in advancing cancer treatment strategies, from deep molecular insights to predictive biomarkers. BostonGene will also exhibit at booth 514.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced its participation in Pathology Visions, taking place November 3-5, 2024, at the Hyatt Regency in Orlando, Florida. Pathology Visions brings together digital pathology experts and professionals to explore current and practical applications and future innovations shaping the field. This event offers a unique opportunity for immersive learning, featuring expert insights, groundbreaking research and exceptional networking opportunities.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced its participation in the Advancing Precision Medicine (APM) Annual Conference 2024, taking place November 1-2, 2024, at the Pennsylvania Convention Center in Philadelphia.

Fujita Health University and BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced today that the Fujita Health University Haneda Clinic will now offer genomic profile testing for cancer patients utilizing the BostonGene Tumor Portrait™ test.

BostonGene, a leading provider of AI-driven, molecular and immune profiling solutions, and Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, today announced a collaboration aimed at integrating innovative molecular testing and informatics platforms into clinical decision-making processes at SCRI phase 1 clinics. Additionally, the collaboration seeks to validate novel biomarkers using BostonGene’s AI-powered multiomics platform in real-world cancer populations.

BostonGene, a leading provider of artificial intelligence (AI)-driven molecular and immune profiling solutions, announced that it will collaborate with Takeda on immuno-oncology focused research studies. This partnership aims to identify key molecular drivers and predictive markers for treatment efficacy and adverse effects with the primary goal of advancing clinical solutions and improving patient outcomes.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, and Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, a research-focused medical school dedicated to discovering, developing and delivering lifesaving treatments, today announced a master agreement to propel collaborative research between the two organizations. Leveraging BostonGene's expertise in AI-powered molecular and immune profiling solutions and Sylvester’s extensive research capabilities, the collaboration will focus on validating blood- and bone marrow-based assays for hematological cancers.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced that it will participate in the hubXchange’s Immuno-Oncology Xchange - Boston 2024, taking place June 18 in Boston, Massachusetts. The event brings together executives from pharma and biotech to address and find solutions to the key issues that are currently faced in Immuno-Oncology.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced that seven abstracts have been accepted for the 2024 ASCO Annual Meeting (ASCO), scheduled to take place May 31 – June 3, 2024, at McCormick Place Convention Center in Chicago, IL. BostonGene will deliver one oral presentation and present two posters, while four abstract presentations will be available online. BostonGene will also exhibit at booth 22157.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, and the Medical College of Wisconsin, today announced the manuscript “Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for PDAC'' has published online and in print in Gastroenterology, the premier journal in the field of gastrointestinal disease. BostonGene’s artwork was also chosen for the cover of the May publication. The journal highlights original research, reviews and expert insights in adult and pediatric gastroenterology and hepatology, covering clinical, translational and basic aspects of the digestive system, liver, pancreas and nutrition. The study identified four distinct tumor microenvironment (TME) subtypes, unveiling a promising path forward in the fight against PDAC and underscoring the importance of considering TME features in personalized therapeutic strategies.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, and the Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world, announced today the launch of a collaboration aimed at uncovering molecular mechanisms underlying IO treatment response and treatment-related toxicity in advanced cancer patients and discovering actionable blood-based biomarkers.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, and Saga University located in Saga, Japan and known for its commitment to educating and training researchers and professionals in the medical and healthcare fields, announced today the launch of a collaboration aimed at discovering biomarkers for immunotherapy (IO) treatment response and treatment-related toxicity in advanced non-small cell lung cancer (NSCLC) patients.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced that eight abstracts were selected for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, which will be held from April 5 - 10, at the San Diego Convention Center in San Diego, CA. BostonGene will exhibit at booth #847.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced today that it has been named as a qualified contract research organization (CRO) of Akoya Biosciences (Nasdaq: AKYA; “Akoya”). By combining Akoya's single-cell imaging solutions with BostonGene's unparalleled expertise in spatial proteomics sample processing and analysis, researchers will gain unprecedented access to the intricate landscape of cellular biology, paving the way for groundbreaking discoveries and highly effective therapeutic strategies.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced it has received four Clinical Trials Arena Excellence Awards in the categories of Business Expansion, Innovation and Product Launches. These awards underscore BostonGene’s commitment to advancing personalized therapies and improving outcomes for cancer patients and individuals with immune-related diseases.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the publication of the manuscript, “Multi-omic Profiling of Follicular Lymphoma Reveals Changes in Tissue Architecture and Enhanced Stromal Remodeling in High-Risk Patients” in Cancer Cell, a premier peer-reviewed scientific journal that publishes high-impact results in cancer research and oncology.

BostonGene, a leading provider of molecular and immune profiling solutions, has been awarded the 2024 Frost & Sullivan Enabling Technology Leadership Award.

BostonGene, a leading provider of AI-driven molecular genetic and immune profiling solutions, today announced the appointment of Joe Lennerz, MD, PhD, as Chief Scientific Officer, Mark Hiatt, MD, MBA, MS, as Senior Vice President of Market Access and Strategy and Ned Segal as a member of the Board of Directors. These appointments underscore BostonGene’s commitment to transformative, AI-integrated molecular analytics and biomarker discovery in the precision medicine space and improve the lives of patients living with cancer and other immune-related diseases.

BostonGene, a leading provider of AI-based molecular and immune profiling solutions, announced today that it will participate in the 21st Japanese Society of Medical Oncology (JSMO) Annual Meeting. The research conference will be held at the Nagoya Congress Center from February 22 to 24, bringing together a diverse tumor-agnostic academic society focused on pharmacologic therapy with the objective of delivering research to enhance the quality of life for all cancer patients.

BostonGene, a leading provider of AI-based molecular and immune profiling solutions, announced today that it will participate in and present at the SLAS2024 International Conference and Exhibition on February 3 - 7, 2024, in Boston, MA at the Boston Convention & Expo Center. This global event brings together a diverse community of scientists from academia, government and industry who are collectively focused on leveraging the power of technology to transform research.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced a master agreement with Duke University School of Medicine, one of the nation's leading institutions for healthcare education, clinical healthcare provision, biomedical research, and community engagement, to collaborate on multiple research projects across lung cancer, gastrointestinal, genitourinary and skin cancers.

BostonGene, a leading provider of AI-driven, molecular and immune profiling solutions, today announced that it has been named a leading innovator in AI drug repurposing in a recent report published in Pharmaceutical Technology, part of the GlobalData network. The article, "Innovators in AI Drug Repurposing: Pioneering AI in the Pharmaceutical Industry," showcases BostonGene at the forefront of innovation by leading in both geographical reach and application diversity. BostonGene's groundbreaking contributions to the pharmaceutical industry, driven by in artificial intelligence (AI)-based and advanced bioinformatics solutions, with the company holding more than 200 patents, solidified its leadership position in total patent count.

BostonGene, a leading provider of AI-based molecular and immune profiling solutions today announced the online publication of the manuscript, “Spatial Mapping of Human Hematopoiesis at Single Cell Resolution Reveals Aging-Associated Topographic Remodeling,” in Blood, the most cited peer-reviewed publication in the field of hematology.

BostonGene, a leading AI-based molecular and immune profiling solutions provider, and the Sarcoma Oncology Center, announced a collaboration to expedite the availability of DeltaRex-G. This groundbreaking platform therapy, authorized by the FDA's Center for Biologics Evaluation and Research (CBER), holds immense promise for patients battling advanced pancreatic cancer, osteosarcoma, soft tissue sarcoma, and breast cancer. The designation of DeltaRex-G, a CCNG1 inhibitor, as a platform therapy with the potential to incorporate other FDA-approved drugs, was enabled by BostonGene's pivotal identification of elevated CCNG1 levels in these different cancer types.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the selection of four abstracts for oral presentation, four abstracts as poster presentations, and two abstracts for online publication at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, California and virtually. BostonGene will exhibit in booth #2350.

BostonGene, a leading provider of AI-driven, molecular and immune profiling solutions, today announced that two abstracts have been accepted for poster presentations for the 2023 San Antonio Breast Cancer Symposium (SABCS), which will be held December 5 - 9, 2023, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. BostonGene will also exhibit at booth 1515.

BostonGene, a leading provider of AI-driven, molecular and immune profiling solutions, announced today that it has won the 2023 Fierce Life Sciences Innovation Award for its AI-driven clinical trials selection tool. The program, produced by Fierce Biotech and Fierce Pharma, recognizes innovations that exemplify effectiveness, technical innovation, competitive advantage, financial impact, and true innovation with the potential to transform the industry.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions today announced that an abstract has been accepted as a poster presentation for the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, which will be held November 14 - 18, 2023, at the Salt Palace Convention Center in Salt Lake City, UT. During the event, BostonGene will also deliver a presentation at the AMP Corporate Workshop day and exhibit at booth 1301.

 

BostonGene, a leading provider of AI-driven, molecular and immune profiling solutions, and LegoChem Biosciences, Inc. (LCB), a clinical-stage biopharmaceutical company developing next-generation, antibody-drug conjugates (ADCs), announced a collaboration to support the Phase I/II study of LCB84, a TROP2-directed ADC, in patients with advanced cancers. This first-in-human study is being conducted at leading cancer institutions in the US and Canada to evaluate the safety and preliminary efficacy of LCB84, both as a single-agent therapy and in combination with an immune checkpoint inhibitor (anti-PD-1 antibody).

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced its abstract has been accepted for poster presentation at the 2023 CTOS Annual Meeting being held November 1-4, 2023, in Dublin, Ireland.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, and FibroFighters, a patient-centric advocacy and education organization dedicated to helping patients and caregivers affected by Fibrolamellar Carcinoma (FLC), have announced a collaboration to advance clinical care for FLC patients.

BostonGene, a leading provider of AI-driven, molecular and immune profiling solutions and Exigent Research, an independent community oncology research network, announced the BostonGene and Exigent Genomic INsight (BEGIN) Study, designed to demonstrate the clinical benefits of using BostonGene Tumor Portrait™ test for advanced cancer patients in a community setting. The BEGIN Study will validate improved patient outcomes by tailoring treatments based on combined WES and RNA-seq coupled with AI-powered analytics.

BostonGene, a leading provider of AI-based molecular and immune profiling solutions, announced today that it will present three abstracts at ESMO Congress 2023. This highly influential oncology event brings together clinicians, researchers, patient advocates, journalists and healthcare industry representatives from around the world to exchange and debate translational cancer science, present potentially practice-changing data and stimulate multidisciplinary discussions to improve treatment options for our patients. The event will be held on October 20 - 24, 2023, in Madrid, Spain, at the IFEMA MADRID. BostonGene will also exhibit in Hall 5, booth 550.

BostonGene, a leading provider of AI-based molecular and immune profiling solutions, today announced a master agreement with Johns Hopkins University School of Medicine (JHUSOM) to collaborate on multiple clinical research projects. The agreement allows BostonGene and JHUSOM to further identify and validate novel precision medicine approaches.

BostonGene, a leading provider of AI-based molecular and immune profiling solutions, announced today that it will participate in and present at the Festival of Genomics & Biodata, the world’s largest genomics & biodata annual meeting that brings together scientists, researchers, clinicians, technology companies, investors and patient organizations to realize the true potential of genomics medicine and related applications, which is being held October 5 - 6, 2023 in Boston, MA at the Boston Convention & Expo Center. BostonGene will also exhibit at booth 17.

BostonGene, a leading provider of AI-based molecular and immune profiling solutions, announced today that it will participate in the 82nd Annual Meeting of the Japanese Cancer Association (JCA). The event, to be held at Pacific Convention Plaza Yokohama from September 21 – September 23, focuses on all aspects of cancer research, including basic, clinical and translational research into the etiology, prevention, diagnosis, and treatment of cancer. BostonGene will also exhibit in booth 56.

BostonGene, a leading provider of AI-based molecular and immune profiling solutions, NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies, and Japan Industrial Partners, a leading Tokyo-based private equity firm, today announced the formation of BostonGene Japan Inc., a Tokyo-based joint venture aimed at advancing personalized medicine and dramatically improving patient outcomes. The new company will utilize BostonGene’s high-complexity molecular technology and advanced biocomputational algorithms, including BostonGene Tumor Portrait™ tests, to accelerate the development and validation of novel precision medicine approaches.

BostonGene announced today that it will participate in and present at the 11th Annual Immuno-Oncology Summit, the leading annual meeting focusing on the next wave of biotherapeutics, advances in technologies, and the valuable exchange of high-quality research from all disciplines of immuno-oncology, which is being held August 7 – 9, 2023 in Boston, MA. BostonGene will also exhibit at the conference, booth #20.

BostonGene announced today the launch of its CLIA-certified and CAP-accredited Liquid Biopsy, Immunoprofiling and Spatial Proteomics solutions that provide a holistic view of a patient’s disease by integrating multiple AI-based molecular and immune profiling techniques that analyze tumor, microenvironment, and host immunity. The new offerings, in addition to the BostonGene Tumor PortraitTM test, will support and improve the efficacy of clinical trials and research and development efforts. The solutions will ensure clinical trial populations are well-defined and representative, assess the safety and effectiveness of treatment while monitoring side effects and select the appropriate patient populations for myriad therapies.

BostonGene today announced that four abstracts have been accepted for poster presentations and two abstracts have been accepted for online publication for the 2023 ASCO Annual Meeting (ASCO), which will be held June 2 – 6, 2023, at McCormick Place Convention Center in Chicago, IL. BostonGene will also exhibit at booth 28155.

BostonGene today announced a collaboration with Sylvester Comprehensive Cancer Center to study the tumor microenvironment (TME) and mutational landscape of patients with high-grade B-cell lymphoma (HGBCL).

BostonGene today announced that eight abstracts were selected for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, which will be held from April 14 – 19, at the Orange County Convention Center in Orlando, FL. BostonGene will exhibit at booth #1358.

BostonGene today announced a collaboration with Little Warrior Foundation to drive the discovery, validation, and implementation of novel liquid biopsy solutions into sarcoma clinical practice.

BostonGene today announced that four abstracts have been accepted for poster presentations for the 2022 San Antonio Breast Cancer Symposium (SABCS), which will be held December 6 - 9, 2022, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. BostonGene will also exhibit at booth 107.

BostonGene Corporation announced the online publication of the manuscript, “Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity” in Cell Reports, a peer-reviewed open access journal that publishes high-quality scientific research and new biological insights across the entire life sciences spectrum. The study, conducted in collaboration with researchers at Washington University School of Medicine in St. Louis, revealed that intratumor spatial heterogeneity (ITH) occurs in clear cell renal cell carcinoma (ccRCC), which may drive clinical heterogeneity and warrants further investigation to improve patient outcomes.

BostonGene announced today that it will participate in the 81st Annual Meeting of the Japanese Cancer Association. The event, to be held at Pacific Convention Plaza Yokohama from September 29 – October 1, will bring together leading oncologists and basic and clinical researchers in academia or industry to discuss cutting-edge findings in cancer research and recent progress in cancer, such as genomic medicine and immune therapy. BostonGene will also exhibit in Hall B, booth 87.

BostonGene today announced the online publication of the manuscript, “Precise reconstruction of the tumor microenvironment using bulk RNA-seq and a unique machine learning algorithm trained on artificial transcriptomes” in Cancer Cell, a premier peer-reviewed scientific journal that publishes high impact results in cancer research and oncology. The study demonstrated the ability of the BostonGene-developed unique and robust machine learning (ML) algorithm named Kassandra to digitally reconstruct the tissue tumor microenvironment (TME) and blood cellular composition, identifying over 50 unique cell populations in total from RNA-seq derived from both archival and fresh tissues. These results indicate that cellular deconvolution can be utilized in future clinical applications to predict blood and tissue microenvironment composition, a critical factor in cancer pathogenesis, clinical outcome, and therapeutic resistance.

BostonGene today announced that three abstracts have been accepted for poster presentations and one abstract has been accepted for online publication for the 2022 ASCO Annual Meeting (ASCO), which will be held June 3 – 7, 2022, at McCormick Place Convention Center in Chicago, IL. BostonGene will also exhibit at booth 27087.

BostonGene today announced a strategic agreement with the National Comprehensive Cancer Network® (NCCN®) to integrate its Clinical Practice Guidelines into the BostonGene Tumor Portrait™ Test reports.

BostonGene today announced that six abstracts were selected for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022, which will be held from April 8 – 13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. In addition, BostonGene will exhibit at booth #3641.

BostonGene today announced the completion of the $150 million Series B funding. NEC Corporation (NEC; TSE: 6701) led the financing with participation from Impact Investment Capital and Japan Industrial Partners. The capital will be used to scale BostonGene’s growth, including continued innovation, clinical and research partnerships, and international expansion. Further, leveraging NEC’s robust infrastructure, BostonGene and NEC intend to form a joint venture to bring lifesaving solutions to patients in Japan and other Asian countries.

BostonGene today announced its publication, “Conserved pan-cancer microenvironment subtypes predict response to immunotherapy,” has been selected by Cancer Cell as one of ten research articles that represent cutting-edge areas of cancer research and oncology in 2021.